By Life Sciences Report : (Editors' Note: This article covers a micro-cap stock. Please be aware of the risks associated with these stocks.) Charming and smart, Chen Lin makes a lot of money by jumping in and out of the highly volatile biotech market while obeying a set of simple rules, which he ...
Vanda Pharmaceuticals ( VNDA ) Q4 2013 Earnings Call February ..... to the Fourth Quarter 2013 Vanda Pharmaceuticals Earnings Conference Call ..... you for joining us to discuss Vanda Pharmaceuticals Fourth Quarter and Full Year
Vanda Pharmaceuticals Inc. ( VNDA ): Q4 EPS of -$0.23 misses by $0.07 . Revenue of $8.8M (+11.4% Y/Y) beats by $0.3M . Press Release Post your comment!
HIMX , HOT , IFF , JAH , LPX , LYG , MFA , MFC , MPEL , NGLS , NLSN , NTWK , O , OAK , OMG , ONE , ORB , OWW , PAG , PDS , PEP , PES , PVR , Q , RTIX , SHPG , SKYW , SON , STC , SYNT , TAP , TCK , TRGT , VNDA , VNTV , WBC , WSO 3 comments!
HOT , IFF , JAH , LPX , LYG , MFA , MFC , MPEL , NGLS , NLSN , NTWK , O , OAK , OMG , ONE , ORB , OWW , PAG , PDS , PEP , PES , PVR , Q , RTIX , SHPG , SKYW , SON , STC , SYNT , TAP , TCK , TRGT , VNDA , VNTV , WBC , WSO Post your comment!
By Scott Matusow : Written by Kyle Dennis and Scott Matusow Today we are going to take a look at a developmental biotech which well-known biotech institutional investor firm Baker Brothers LLC has a substantial position in. The company is developing a blood test which is designed to inactivate a ...
GIG +10% . KOOL +10% . TASR +9% . KTOS +9% . IPCI +8% . Top 10 Losers: STWD -20% . ORMP -19% . GALE -18% . INFU -15% . VNDA -15% . DRNA -14% . OKE -14% . YOD -12% . MAMS -12% . QKLS -11% . Post your comment!
Jan 31 (Reuters) - Vanda Pharmaceuticals Inc said on Friday that U.S. health regulators have approved its drug Hetlioz to regulate the internal body clocks of blind patients and help normalize sleep...
Vanda Pharmaceuticals ( VNDA +15.2% ) shoots higher after it says the FDA approved Hetlioz ..... affects the majority of totally blind people; ~80K live in the U.S. VNDA anticipates making Hetlioz commercially available in the second quarter
following Fanapt's approval, raising doubt about management's view of Vanda's future, in our opinion. Vanda Pharmaceuticals focuses on the development and commercialization of therapies for central nervous system disorders. Its lead